Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time - BOULDER, Colo., Sept. 22,...